Diseases [C] » Nervous System Diseases [C10] » Neuroinflammatory Diseases » Meningitis
Description
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) MeSH
Hierarchy View
Subtype Terms (6)
Arachnoiditis
3 approved drugs
Meningitis, Aseptic
3 approved drugs
Meningitis, Bacterial
19 drugs (13 approved, 6 experimental)
Meningitis, Fungal
2 approved drugs
Meningitis, Viral
1 approved drug
Meningoencephalitis
3 approved drugs
Approved Indicated Drugs (10)
Phase 4 Indicated Drugs (13)
acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)
Bivalent group A and C meningococcal vaccine (Menomune-A/C)
diphtheria, tetanus and whole cell pertussis vaccine (Boostrix)
Phase 3 Indicated Drugs (16)
Phase 2 Indicated Drugs (13)
DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (48)
Badalona Hospital Germans Trias i Pujol
Bill and Melinda Gates Foundation
Centers for Disease Control and Prevention (CDC)
Foundation for Paediatric Research, Finland
Hospital Universitari de Bellvitge
Hospital Universitario Virgen Macarena
Infectious Disease Institute, Kampala, Uganda
Maryland Department of Health and Mental Hygiene
Mbarara University of Science and Technology
National Institute of Allergy and Infectious Diseases (NIAID)
Organization Involved with Phase 3 Indications (56)
All India Institute of Medical Sciences
Beijing Minhai Biotechnology Co., Ltd
Bharati Hospital and Research Center
Chinese Academy of Medical Sciences
CHU Kamenge, Bujumbura, Burundi
Department of State for Health and Social Welfare, The Gambia
Dr. D. Y. Patil Dental College & Hospital
Eijkman Institute for Molecular Biology, Jakarta, Indonesia
European and Developing Countries Clinical Trials Partnership (EDCTP)
French National Agency for Research on AIDS and Viral Hepatitis
Hualan Biological Engineering, Inc.
Indian Council of Medical Research
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)
Papua New Guinea Institute of Medical Research
Pham Ngoc Thach University of Medicine
Serum Institute of India Pvt. Ltd.
Organization Involved with Phase 2 Indications (44)
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Armauer Hansen Research Institute, Ethiopia
Bambino Gesù Hospital and Research Institute
Chesapeake Research Group, LLC
Global Alliance for TB Drug Development
Health Protection Agency, United Kingdom
Institut National de la Santé Et de la Recherche Médicale, France
Organization Involved with Phase 1 Indications (20)
Organization Involved with Other Experimental Indications (12)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
